Unexpected evolutionary benefit to phages imparted by bacterial … – Science Advances
|
Unexpected evolutionary benefit to phages imparted by bacterial …
Science Advances Bacteria and bacteriophages arm themselves with various defensive and counterdefensive mechanisms to protect their own genome and degrade the other’s. CRISPR (clustered regularly interspaced short palindromic repeat)–Cas (CRISPR-associated) is an … Crispr And Crispr-Associated (Cas) Genes Market Analysis and …MilTech |
NEXTpittsburgh |
UPMC and Pitt announce $200 million for immunotherapy research and new collaboration center
NEXTpittsburgh Work will soon begin on a 200,000-square-foot building on the border of Shadyside and Bloomfield where some of Pittsburgh’s biggest names in medicine and engineering aim to make huge strides in immunotherapy. “Two of Pittsburgh’s research powerhouses … Trib editorial: UPMC-Pitt immunotherapy center advances city’s medical legacyTribune-Review Immunology Research Center Planned For Site Of Old Auto Plant On Baum Boulevard90.5 WESA |
Science Daily |
In effort to treat rare blinding disease, researchers turn stem cells into blood vessels
Science Daily Now, in a study published February 13 in Science Signaling, Lin’s team discovered that a chemical compound that activates ATF6 also converts patient-derived stem cells into blood vessels. “We wanted to see if there was a way to correct this gene defect … |
Life Sciences Intellectual Property Review |
Cellectis to license recently-granted CRISPR patents
Life Sciences Intellectual Property Review Both patents centre on the use of CRISPR technology in T cells and “claim methods by which T cells are gene edited using transient expression of CRISPR/Cas9 components”, according to the release. Last year, Cellectis was granted European patent number … Rupert BealeLondon Review of Books America May Fall Behind in Genetic Technologies, and That’s OKChristian Post |
Xconomy |
Astellas Buys Stem Cell Gene-Editing Firm for $102.5M
Xconomy Universal Cells’ technology aims to make stem cells that don’t have some of the problems that current cell therapies face, such as the immune rejection of transplanted cells. This is an attractive prospect for Astellas, which has been working to get … Astellas pledges $102.5M for universal donor cell companyFierceBiotech Astellas Acquires Universal Cells, Inc.Markets Insider Astellas upgrades Universal Cells licensing deal to a buyThe Pharma Letter DEALSTREETASIA all 6 news articles » |